00

Pacific Shuanglin Bio-pharmacy Co LtdSHE 000403 Stock Report

Last reporting period 31 Dec, 2022

Updated 18 Sep, 2024

Last price

Market cap $B

2.223

Small

Exchange

XSHE - Shenzhen Stock Exchange

000403.SZ Stock Analysis

00

Neutral

Based on Eyestock quantitative analysis, 000403.SZ`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

82/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

190.1 %

Greatly undervalued

Market cap $B

2.223

Dividend yield

1.05 %

Shares outstanding

728.93 B

Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in the production and marketing of pharmaceutical products. The company is headquartered in Zhanjiang, Guangdong and currently employs 1,627 full-time employees. The firm's main products are human albumin, intravenous immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin and rabies immunoglobulin. The firm mainly operates its business in the domestic market.

View Section: Eyestock Rating